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abstract
PURPOSE To evaluate health care systems for the availability of population-level data on the frequency of use and
results of clinical molecular marker tests to inform precision cancer care.
METHODSWe assessed cancer-related molecular marker test data availability across 12 US health care systems
in the Cancer Research Network. Overall, these systems provide care to a diverse population of more than 12
million people in the United States. We performed qualitative analyses of test data availability for five blood-based
protein, nine germline, and 14 tissue-based tumor marker tests in each health care system’s electronic health
record and tumor registry using key informants, test code lists, and manual review of data types and output. We
then performed quantitative analyses to estimate the proportion of patients with cancer with test utilization data
and results for specific molecular marker tests.
RESULTS Health systems were able to systematically capture population-level data on all five blood protein
markers, six of 14 tissue-based tumor markers, and none of the nine germline markers. Successful, systematic
data capture was achievable for tests with electronic data feeds for test results (blood proteinmarkers) or through
prior manual abstraction by tumor registrars (select tumor-based markers). For test results stored in scanned
image files (particularly germline and tumor marker tests), information on which test was performed and test
results was not readily accessible in an electronic format.
CONCLUSION Even in health care systems with sophisticated electronic health records, there were few codified
data elements available for evaluating precision cancer medicine test use and results at the population level.
Health care organizations should establish standards for electronic reporting of precision medicine tests to
expedite cancer research and facilitate the implementation of precision medicine approaches.
JCO Clin Cancer Inform. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Recent advances in precision medicine have resulted
in national guidelines that require the implementation
of precision approaches in clinical care.1,2 In cancer,
precision medicine uses specific characteristics of
patients and their tumors to develop tailored care plans
and treatment regimens. Applications of precision
medicine technologies include using blood-based
protein markers to predict patient prognosis and
monitor patients for recurrence,3-6 identifying patients
who are at a high risk for cancer using germline genetic
tests,7-9 and analyzing molecular markers in tumor
tissue to characterize patients’ risk of recurrence and
tumor susceptibility to specific targeted therapies.10-13
Precision medicine has enormous potential to improve
cancer care. However, there are many unanswered
questions about the impact of precision medicine
on survival, quality of life, patient costs, health sys-
tem costs, and health disparities in real-world clini-
cal settings (as opposed to in clinical trials). The
population-level value, including long-term outcomes,
of some precision medicine technologies, including
those that are now standard of care, remains poorly
understood.14 These evidence gaps make it difficult to
generate clinical practice guidelines and secure re-
imbursement for many molecular assays and tests,15
and there is a need to incorporate real-world evidence
to assess the effectiveness, value, and equitable use of
these tests in clinical settings.16-19
There are also challenges to implementing recom-
mended precision medicine technologies in clinical
settings and evaluating relevant outcomes.20 Specifically,
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although there are clinical guidelines from professional
societies about precision medicine,21-23 many health care
systems have not widely or comprehensively adopted
standardized protocols governing when and how to use
recommended genetic, molecular, and protein blood
marker tests. Importantly, most new cancer therapies focus
on specific aberrant molecular pathways. Given their
narrow applications and expense, the use of novel targeted
therapies should be guided by molecular tests to determine
which patients are most likely to benefit.24-26 Inappropriate
use of targeted therapies in patients who have not un-
dergone required or recommended testing or who do not
have the correct therapeutic target(s) has been previously
demonstrated.27,28 Thus, it is important for health care
systems to be able to evaluate the use and results of
molecular assays, genetic testing, and targeted therapies,
along with their impacts on patient outcomes.
Access to accurate, reliable, and longitudinal data about
biomarker and genetic test use and results in large pop-
ulations across diverse health care systems is required to
gain a better understanding of the benefits, risks, costs, and
value of precision medicine approaches in cancer care.29
Here, we describe the current availability of population-level
health system data on the use of, and results for, clinical tests
of blood-based protein markers, germline markers, and
tissue-based tumor markers across health systems in one of
the largest cancer research collaborations in the United
States, the Cancer Research Network (CRN).30,31 We also
outline the challenges of capturing population-level data on
molecular marker testing in clinical practice and provide
recommendations for increasing capacity to evaluate and
improve the use of precision medicine in cancer care.
METHODS
This analysis was conducted under data infrastructure
activities within the CRN, which was approved by the
primary CRN Institutional Review Board at Kaiser Perma-
nente Northern California with ceding of institutional review
board oversight of these activities from the other partici-
pating sites. We performed qualitative analyses of test data
availability using key informants who were specialty-
specific experts in the fields of pathology, oncology, and
health informatics. We also assessed test code lists and
performed a manual review of data types and output. We
then performed quantitative analyses to estimate the
number and proportion of patients with cancer that have
test utilization data and results available for specific mo-
lecular marker tests, as described later in Methods.
Population and Setting
The analysis involved 12 geographically distributed US
health care organizations that provide care to a diverse
population of more than 12 million people (Fig 1). All or-
ganizations are members of the CRN30,31 and are part of the
larger Health Care Systems Research Network, an estab-
lished consortium of 20 research centers affiliated with
large, integrated health care systems.32 The CRN was
established in 1998 to facilitate multisite collaborative re-
search on cancer prevention, screening, treatment, sur-
vival, and palliation in diverse populations. The CRN
comprises the National Cancer Institute and nonprofit re-
search centers affiliated with these integrated health care
delivery systems. These systems include both enrolled
health plan members and aligned patients. Members are
enrolled through employer-sponsored insurance, individual
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FIG 1. Cancer Research Network sites contributing data to assess capture of molecular marker information in electronic health records.
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insurance plans, and capitated Medicare and Medicaid
programs. Aligned patients use system medical group
providers. Members served by these systems are generally
representative of each system’s geographic service area.33
Data Sources
Data were obtained from the Health Care Systems Re-
search Network Virtual Data Warehouse (VDW) from Jan-
uary 1, 2005, through December 31, 2015. The VDW is
a series of data standards and automated processes that
guide the generation of similarly constructed data tables at
each organization to facilitate multisite research projects.34
Developed in collaboration with CRN members, the VDW
includes information on demographics, health plan en-
rollment, pharmacy fills, diagnoses from inpatient and
outpatient care, utilization of procedures, laboratory values,
and vital signs. At each site, data from health system or
health plan administrative and claims databases and
electronic health records (EHRs) are extracted, trans-
formed, and loaded into the VDW common data model
format.
The VDW also includes tumor registry data consistent with
the standards of the North American Association of Central
Cancer Registries and the National Cancer Institute’s SEER
program. These data include information on all cancer
types, including each patient’s cancer site, sequence, di-
agnosis date, stage, and site-specific factors (data items on
tumor characteristics, prognosis, predicted treatment re-
sponse, and clinical significance), based on the American
Joint Committee on Cancer Collaborative Stage Data Col-
lection System,35 and receipt of primary chemotherapy,
immunotherapy, hormone therapy, surgical treatment, and
radiotherapy. Data contained within the tumor registries
were collected by certified tumor registrars who review all
elements of each patient’s medical record, including pa-
thology reports, laboratory test results, imaging reports,
infusion session summaries, surgical operation reports,
physician orders, and clinician progress notes.
Assessment of Molecular Marker Data Availability
We used a multipronged approach to identify data sources
for blood-based protein, germline, and tissue-based tumor
marker tests. For blood-based protein marker tests, we
focused on cancer antigen (CA) 125, prostate-specific
antigen, CA 19-9, carcinoembryonic antigen, and α-
fetoprotein. For germline tests, we assessed data on
tests that included BRCA1, BRCA2, MLH1, PMS2, MSH2,
MSH6, EPCAM, FAP, andMUTYH. For tissue-based tumor
marker tests, we evaluated the availability of data on tests of
relevance to breast (estrogen receptor [ER], progesterone
receptor [PR], human epidermal growth factor receptor 2
[HER2], and multigene signature panel results), colorectal
(BRAF, KRAS, and microsatellite instability status), and
lung (ALK, PDL1, EGFR, ROS1, RET, KRAS, and MET)
cancers.
These markers were selected via a consensus process and
consultation with specialty-specific experts based on each
marker’s importance for driving decisions about patient
care or because they were the focus of a current or planned
CRN research project. We identified these markers within
the VDW data using a combination of methods, including
the use of standard Current Procedural Terminology pro-
cedure codes, International Classification of Diseases (ICD)
Ninth Revision and ICD-10 diagnostic codes, and site-
specific factor variables within the tumor registries. Out-
side the VDW, we used custom health system–specific
codes that were identified via text searches of health system
diagnosis and procedure code descriptions.
KRAS Mutation Testing in Colorectal Cancer
In an exploratory analysis of KRAS mutation testing in
colorectal cancer tissue biopsies, we used Kaiser Perma-
nente Colorado as a test site to investigate the use of
text-mining approaches in pathology reports to identify
molecular tests and results. We identified all colorectal
cancers occurring from 2010 to 2015 at Kaiser Perma-
nente Colorado using the tumor registry data and co-
lorectal cancer–specific ICD for Oncology, Third Edition,
diagnosis codes. In this cohort of colorectal cancers, we
electronically tagged the following terms in patient pa-
thology reports: KRAS, mutation, and molecular. We then
assessed the sensitivity and specificity of this text mining
approach to identify KRAS mutation testing against the
gold standard assessment of KRAS testing utilization and
results from the tumor registry.
Evaluation of Site-Specific Factor Variables for
Breast Cancer
Because breast cancer is one of the best-annotated
cancers for site-specific factor variables in tumor reg-
istry data, we used breast cancer as a case example to
demonstrate how standardized, systematic documen-
tation allows for population-level assessment of molec-
ular marker test utilization and results across time and
health systems. Relevant site-specific factors collected in
relation to breast cancer include ER, PR, and HER2
status and multigene expression profiles. Possible values
for site-specific factor results include the following:
“positive/elevated,” “negative/normal,” “borderline,”
“not applicable/no information collected,” “ordered/not
interpretable,” “test ordered, no results,” “test not
done,” and “unknown or no information.” Across 12
sites, we identified all individuals with a breast cancer
diagnosis (C50.x based on ICD for Oncology, Third
Edition, codes) between January 1, 2005, and December
31, 2015. We summed the number of individuals with
available site-specific factor test results defined as the
presence of structured results data (ie, positive, negative,
normal, borderline) or the presence of a numeric value
for a risk score associated with multigene expression
profiles. A structured data reporting test not done, results
Molecular Marker Data Capture in the Cancer Research Network
JCO Clinical Cancer Informatics 3
Downloaded from ascopubs.org by University of Massachusetts on October 25, 2019 from 146.189.228.234
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
not in the chart, unknown, or not interpretable were
considered unavailable test results. We calculated the
proportion of available site-specific factor test results in
the VDW tumor registry among identified patients with
breast cancer by site and year.
RESULTS
The ability of each CRN health system to electronically
capture data on the use and results of clinical biomarker
and genetic tests varied according to the type of test and the
way in which the test results were stored in the VDW and
EHR. Here, we detail the availability of biomarker and
genetic testing data in the EHR at CRN sites by type of test.
This information is also summarized in Table 1.
Blood-Based Protein Markers
Information on blood-based protein markers resided in the
following three locations: VDW tumor registry, VDW labo-
ratory table, and the EHR’s laboratory management system.
Carcinoembryonic antigen, α-fetoprotein, and CA 19-9 test
utilization and test values were available for all patients with
specific GI cancers as site-specific factor variables in the
VDW tumor registry. However, the VDW did not capture
results of these tests for patients without cancer (Table 1).
CA-125 and prostate-specific antigen test utilization and
results were documented as site-specific factor variables
for ovarian cancer and prostate cancer, respectively, in the
VDW tumor registry. These tests were also standardly
captured in the VDW laboratory table at most CRN sites,
TABLE 1. Clinical Biomarker and Genetic Marker Data Assessed in the Cancer Research Network
Molecular Marker Marker Type Cancer Site Data Source
CA-125 Blood-based protein Ovarian VDW laboratory table; VDW tumor
registry; EHR laboratory
management system
PSA Blood-based protein Prostate VDW laboratory table; VDW
tumor registry; EHR laboratory
management system
CA 19-9 Blood-based protein Pancreatic, gallbladder,
bile duct, and gastric
VDW tumor registry; EHR
laboratory management system
CEA Blood-based protein Multiple VDW tumor registry; EHR
laboratory management system
AFP Blood-based protein Liver VDW tumor registry; EHR
laboratory management system
BRCA1 and BRCA2 Germline Hereditary breast and ovarian
cancer syndrome, breast,
ovarian, prostate, pancreatic,
melanoma
VDW procedure table; VDW
diagnosis table; EHR scanned
image reports
MLH1, PMS2, MSH2,
MSH6, EPCAM
Germline Lynch syndrome (hereditary
nonpolyposis colorectal
cancer), colorectal and
other GI sites, endometrial,
ovarian, brain, pancreatic,
and skin
EHR scanned image reports
FAP, MUTYH Germline Familial adenomatous
polyposis, colorectal
EHR scanned image reports
Estrogen receptor status,
progesterone receptor
status, HER2, multigene
signature panel
Tissue-based tumor marker Breast VDW tumor registry; EHR
scanned image reports;
pathology reports
MSI status* Tissue-based tumor marker Colorectal VDW tumor registry; EHR
scanned image reports;
pathology reports
KRAS Tissue-based tumor marker Colorectal VDW tumor registry; EHR scanned
image reports; pathology reports
BRAF Tissue-based tumor marker Colorectal, melanoma EHR scanned image reports; pathology reports
ALK, PDL1, EGFR, ROS1,
RET, KRAS, MET
Tissue-based tumor marker Lung EHR scanned image reports; pathology reports
Abbreviations: AFP, α-fetoprotein; CA, cancer antigen; CEA, carcinoembryonic antigen; EHR, electronic health record; HER2, human epidermal growth
factor receptor 2; MSI, microsatellite instability; PSA, prostate-specific antigen; VDW, Virtual Data Warehouse.
*Includes immunohistochemistry and DNA tests.
Burnett-Hartman et al
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which made it possible to systematically analyze test uti-
lization and results in the entire health system membership
across CRN sites for these markers. Finally, we found that
blood-based protein marker data were also stored in the
laboratory management system of the EHR. These data
elements were transferred directly from testing laboratories
electronically, and the results of tests were captured in
standard data fields within the EHR.
Germline Genetic Markers
In each CRN health system, the results of germline tests
were stored as scanned image reports in the EHR. There
were no separate electronic data feeds from testing labo-
ratories for test results. Some germline tests were noted as
text in patients’ clinic visit notes, but the results were not
consistently or standardly documented. Gene-specific
procedure codes were not used for either the individual
gene or panel test results for MLH1, PMS2, MSH2, MSH6,
EPCAM, FAP, and MUTYH. However, for BRCA1 and
BRCA2 testing, standard procedure codes were first used
in health systems in 2013. In some health systems, custom
health system–generated procedure codes were used to
identify specific genetic tests. However, even when we used
the standard procedure codes and the custom health
system–generated procedures codes, population-level data
on use of genetic testing was not captured well by
procedure codes.
Tissue-Based Tumor Markers
Like germline tests, the results of tumor marker tests were
stored in the EHR as scanned image reports at each health
system. Results of tumor marker tests were inconsistently
reported in the text of pathology reports, and these lacked
standard documentation formats. Often, the pathology
report referenced the scanned image results as an ad-
dendum, without describing the type of test performed or
the results of the test. Neither the use nor results of tissue-
based tumor marker tests could be captured in VDW
procedure or diagnoses tables through standard codes.
Among the 14 tissue-based tumor markers that we
assessed, the use and results of six markers were sys-
tematically captured in the VDW tumor registry as site-
specific factor variables. These included all of the breast
cancer tumor markers that we evaluated (ER, PR, HER2,
and multigene signature panels) and microsatellite in-
stability status and KRAS mutation status for colorectal
cancer. However, BRAF mutation status in colorectal
cancer and the lung cancer tumor markers (ALK, PDL1,
EGFR, ROS1, RET, KRAS, and MET) were not in the VDW
tumor registry as site-specific factor variables, likely be-
cause they were not required fields for collaborative staging
at the time of this analysis.
KRAS Mutation Testing in Colorectal Cancer
Exploratory analysis to use text-mining approaches in pa-
thology reports to identify patients with colorectal cancer
who received KRAS mutation tissue testing included
a cohort of 1,567 patients with colorectal cancer diagnosed
from 2010 to 2016 at Kaiser Permanente Colorado. Among
223 patients with KRAS testing confirmed via tumor registry
data, text mining was able to identify 143 patients as having
had a KRAS test (67% sensitivity). Among 1,344 patients
with colorectal cancer who did not have KRAS testing, text
mining was able to correctly classify 1,270 patients as not
having KRAS testing (94% specificity).
Site-Specific Factors for Breast Cancer
All health systems had standardized, structured docu-
mentation of somatic tumor marker testing and results for
breast cancer in the tumor registry. Table 2 lists the number
and yearly proportion of patients with breast cancer with
test results available in the VDW tumor registry for ER, PR,
and HER2 status and for multigene signature scores across
all sites from 2005 through 2015. For ER and PR, all
participating sites had high proportions of patients with
available results from 2005 through 2015, and eight of 12
sites had relatively stable rates over time. HER2 and
multigene results were available from 2010 onward for
all sites.
Most health systems had ER status test results available as
electronic data elements for more than 80% of patients with
breast cancer between 2005 and 2015 (Fig 2). In contrast,
data capture for the multigene signature panel began in
2010, and there was significant variation in the availability
of test results for this panel over time and by health system
(Fig 3).
DISCUSSION
Among the markers investigated in this study, health
systems within the CRN were able to capture population-
level data from standard fields in the EHR or tumor registry
on all five blood protein markers, six of 14 tumor-based
markers, and none of the nine germline markers. The VDW
is one of the most influential common data models and one
of the most distributed health data networks in the United
States for health care research among millions of patients
for more than 20 years, and it preceded and served as
amodel for the US Food and Drug Administration’s Sentinel
and PCORnet data models.36 But even with the VDW’s
depth and breadth of data capture, our results indicate that
currently health systems in the CRN are unable to efficiently
capture molecular testing use or results at the population
level for the majority of cancer types. On a patient-by-pa-
tient basis, the scanned image of the test can be opened
and read and is thus usable for clinical care. However,
unlike other laboratory test results, these data are unable to
be accessed and pooled into an electronic data file across
hundreds or thousands of patients. This provides enormous
challenges for evaluating the use of precision medicine
approaches in real-world clinical settings.
Breast cancer was the only cancer type for which we were
able to assess multiple molecular marker tests across time
Molecular Marker Data Capture in the Cancer Research Network
JCO Clinical Cancer Informatics 5
Downloaded from ascopubs.org by University of Massachusetts on October 25, 2019 from 146.189.228.234
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
and across health systems. The data on breast cancer
molecular markers were available because national can-
cer registry guidelines require standardized reporting
of these markers, so cancer registrars in each health
system manually abstract these data. Thus, successful,
population-level data capture was only achievable for tests
with electronic data feeds for test results (blood protein
markers) or when the molecular marker was manually
abstracted by health system tumor registrars (select tumor-
based markers) from text-based results and converted into
an electronic data element. For test results that were stored
in scanned image files (particularly germline and tumor
marker tests), information on which test was performed and
the results of these tests were not readily accessible for
population-level evaluation of precision medicine ap-
proaches in clinical settings.
Although health systems generally have care pathways and
national guidelines available for patient care, deviations for
these guidelines are commonly reported.37-41 There are
patient factors, including financial burden, that contribute
to the care that a patient receives in the real world.42,43
There are also provider factors, such as specialty and years
in practice, that are associated with variations in care.44,45
Characterizing the patient, provider, and health system
factors that are associated with deviation from guideline-
concordant care pathways for precision oncology is es-
sential to ensuring high-quality, equitable care. To effectively
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FIG 2. Percentage of patients with breast cancer with tumor estrogen receptor status results available in the
Cancer Research Network Virtual Data Warehouse tumor registry by health system from 2005 to 2015.
TABLE 2. Breast Cancer Site–Specific Factor Data Availability in the Cancer Research Network From 2005 to 2015
Year
Total No. of Patients
With Breast Cancer
No. of Patients (%)
Estrogen
Receptor Test
Results Available
Progesterone
Receptor Test
Results Available
HER2 Test
Results
Available
Results Available From
Combined Information From
Estrogen Receptor, Progesterone
Receptor, and HER2 Tests
Multigene Score
Test Results
Available
2005 7,500 6,619 (99) 6,572 (88) 24 (, 1) 21 (, 1) 0 (0)
2006 7,785 6,947 (99) 6,902 (89) 44 (1) 35 (, 1) 2 (, 1)
2007 8,062 7,312 (99) 7,282 (90) 58 (1) 45 (1) 6 (, 1)
2008 8,075 7,258 (99) 7,222 (89) 56 (1) 45 (1) 8 (, 1)
2009 8,693 7,681 (99) 7,627 (88) 160 (2) 181 (2) 29 (, 1)
2010 8,812 7,928 (99) 7,890 (90) 3,855 (44) 4,255 (48) 579 (7)
2011 9,156 8,318 (99) 8,275 (90) 5,630 (61) 4,801 (52) 910 (10)
2012 9,439 8,734 (99) 8,672 (92) 6,145 (65) 5,362 (57) 1,125 (12)
2013 9,594 8,798 (99) 8,732 (91) 6,413 (67) 5,794 (60) 1,244 (13)
2014 9,480 9,016 (99) 8,957 (94) 6,590 (70) 5,951 (63) 1,450 (15)
2015 8,115 7,871 (99) 7,827 (96) 5,667 (70) 5,413 (67) 1,397 (17)
NOTE. Table lists counts of patients with actual test results available, with test results defined as positive, negative, normal, or borderline, or numeric values.
Abbreviation: HER2, human epidermal growth factor receptor 2.
Burnett-Hartman et al
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evaluate precision medicine utilization, costs, and effec-
tiveness within and across health systems, more compre-
hensive and efficient data capture of molecular assay and
genetic testing results is needed.
Possible approaches to improve the population-level data
capture of information needed to evaluate precision
medicine in real-world clinical settings include the follow-
ing: require that laboratories send electronic data to health
care systems for genetic and other molecular marker test
results that conform to Health Level Seven International
(HL7) Fast Healthcare Interoperability Resources (FHIR)
specifications for genomic data46,47; develop and use
standard procedure codes for each molecular marker and
genetic test; develop diagnosis codes for specific genetic
variant carrier status; encourage EHR vendors to in-
corporate standardized tables to capture test status and
results for these tests; and build infrastructure into common
data models, such as the VDW, to incorporate tables that
include structured data on molecular assay and genetic
testing results. Implementing these approaches, which are
not mutually exclusive, will require health systems to invest
resources in data infrastructure, but these improvements
will enhance the quality of care and allow health systems
and researchers to identify ways to optimize the use of
precision medicine approaches in clinical settings.
Several health systems, including Intermountain Health-
care and the US Department of Veterans Affairs, have
begun to work with laboratories to obtain electronic data for
genetic and other molecular marker testing on their
members. In doing so, these health systems are able to
evaluate and improve precision cancer care within their
systems. Two studies at Intermountain Healthcare reported
improved survival and similar or decreased costs associ-
ated with the use of tumor testing to identify targeted cancer
therapies.48,49 Within the US Department of Veterans Af-
fairs, a recent study of patients with lung cancer evaluated
the use of erlotinib, a drug that targets cancers with acti-
vating mutations in the epidermal growth factor receptor
(EGFR) gene. This study found that 11% of patients whose
lung cancer tested negative for EGFR mutations and 17%
of patients with no EGFR test results were treated with
erlotinib.27 This was inappropriate because erlotinib use in
patients with wild-type EGFR lung cancer is associated with
poorer outcomes than platinum-based chemotherapy.50,51
Thus, by obtaining and evaluating electronic data on
molecular marker testing in their members, the Department
of Veterans Affairs was able to identify a specific area for
quality improvement initiatives that may lead to better
patient outcomes.
To reduce inappropriate use of targeted therapies, pre-
authorization and provider attestation to the presence of the
molecular target are often required by insurers, particularly
those that operate outside of the integrated systems de-
scribed in our article.52 In addition, in 2018, the Centers for
Medicare andMedicaid Services released a decisionmemo
noting that next-generation sequencing as a diagnostic
laboratory test is reasonable and necessary and is covered
nationally for patients diagnosed with specific tumor types.
However, this rule change did not come with new or ad-
ditional procedure codes or diagnosis billing codes specific
to gene mutations or other molecular markers of interest.
Thus, codifiable requirements allowing for population-
based identification of the use of tests or codifiable
methods for describing test results are still lacking.
Some health systems have begun to track genetic and other
molecular marker test use through system-generated
modified procedure and diagnostic codes that are spe-
cific to a particular gene or genetic syndrome. This includes
diagnostic codes for specific gene mutation carrier status.
Unfortunately, system-generated codes are not used
consistently and are not applied in a standardized manner
across health systems. The result is missing utilization data
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FIG 3. Percentage of patients with breast cancer with multigene signature results available in the Cancer Re-
search Network Virtual Data Warehouse tumor registry by health system from 2005 to 2015.
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and the inability to conduct research across multiple health
systems. This is important because any one systemmay not
have sufficient power to examine the outcomes of precision
medicine approaches. To improve data capture for these
tests, unique standard procedure, diagnostic, and billing
codes are necessary.53 For some tests, gene-specific billing
codes are available, and a recent study by Lynch et al54
using Medicare claims data demonstrated that gene-
specific billing codes facilitated population-level research
in precision medicine. As new tests are introduced into
clinical practice, it is important to implement new codes in
a rapid fashion, rather than using a generic laboratory test
code that lacks specification of the test used.
Additional data infrastructure is also needed to standardize
the complex data elements that are reported in genetic and
other molecular test results. Results from genetic and other
molecular testing include more information and are re-
ported in a different format than results from traditional
laboratory tests (eg, cholesterol tests, WBC counts) for
which EHR systems were designed to capture. Several
recent studies have successfully used HL7 FHIR data
standards to integrate electronic genomic data with clinical
EHR data.46,55 This integration was for the purpose of
improving patient management, but using the HL7 FHIR
data specifications also has the potential to facilitate the
development and standardization of research-ready data
that include the molecular marker data elements necessary
for population-based research on the use of precision
medicine in clinical practice.
Our assessment of the availability of population-level data to
evaluate precision medicine approaches for cancer care in
real-world clinical settings included 12 diverse health
systems with sophisticated EHRs and multiple data sour-
ces. However, our findings should be considered with
regard to several limitations. Most of the participating health
systems use integrated care delivery models, so our results
may not be generalizable to academic care settings or
medical centers that are primarily fee-for-service models. In
addition, there was significant variation in the depth and
amount of data on molecular marker test use and the re-
sults available in standard fields between cancer types, and
we were unable to assess guideline-concordant test or
therapy use. Despite these limitations, our study highlights
the current challenges systems face even in the environ-
ment of sophisticated EHR data to assess precision cancer
care. In addition, we were able to identify specific areas for
improvement in the way that molecular test use information
and results are stored within the EHR.
Within the CRN health systems, several initiatives are now
underway to improve population-level data capture of
molecular marker testing and to better incorporate mo-
lecular marker data in to the VDW. Work is currently un-
derway to include CA 19-9, carcinoembryonic antigen, and
α-fetoprotein into the VDW laboratory table; this work will
improve the electronic capture of these markers across the
entire membership of CRN health systems. The Henry Ford
Health System has begun to systematically capture the
results of multimarker panel tumor tests in a discreet da-
tabase that can be used for research to evaluate precision
cancer care, and the Kaiser Permanente Center for Ef-
fectiveness and Safety Research is working with testing
laboratories to obtain electronic data on molecular testing
and results within Kaiser Permanente health plan mem-
bers. These efforts will help to facilitate research aimed at
evaluating and optimizing precision medicine in clinical
practice and ultimately lead to better patient outcomes and
improved efficiency by ensuring the implementation of
guideline-based precision cancer care.
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